Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

FDA calls out Merz Pharma Instagram ad as ‘misleading’

The news: The FDA’s Office of Prescription Drug Promotion (OPDP) recently called out Merz Pharma for making misleading claims about one of its products, Xeomin, in an Instagram ad.

  • Xeomin is a prescription injectable medication used to treat wrinkles.
  • The social media post in question was made by Merz on the Xeomin Aesthetics Instagram account, and shared by celebrity interior designer Nate Berkus via a paid brand partnership.

You've read 0 of 2 free articles this month.

Get more articles - create your free account today!